Healthcare / BiotechnologyHKSE
$5.82
+0.09 (+1.57%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 23%
FCF escenarios
weak_data · normalized FCF $-313.3M · quality 66.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
35/100
D
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$3.6B
P/E
582.0x
↑EV/EBITDA
24.5x
↑ROE
0.3%
↓Gross Margin
71.7%
↑Debt/Equity
0.29
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+15.0%
FCF CAGR
—
FCF margin
-26.7%
FCF / Net income
-29.28x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $784.8M · net income $7.1M · FCF $-209.2M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $784.8M | $784.8M | $726.3M | $618.1M | $516.0M |
| Net Income | $7.1M | $7.1M | $73.2M | $-119.4M | $-331.7M |
| EBITDA | $133.6M | $133.6M | $178.7M | $-22.5M | $-245.5M |
| EPS | — | — | 0.14 | -0.23 | -0.67 |
| Gross Margin | 71.7% | 71.7% | 74.7% | 66.2% | 68.7% |
| Operating Margin | 5.2% | 5.2% | 14.4% | -16.9% | -63.2% |
| Net Margin | 0.9% | 0.9% | 10.1% | -19.3% | -64.3% |
| Balance Sheet | |||||
| Debt/Equity | 0.29 | 0.29 | 0.42 | 0.31 | 0.21 |
| Current Ratio | 2.33 | 2.33 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-209.2M | $-209.2M | $-480.8M | $-313.3M | $-408.2M |
| Returns | |||||
| ROE | 0.3% | 0.3% | 4.5% | -9.0% | -23.4% |
| Valuation | |||||
| P/E | 582.00 | 582.00 | 62.43 | — | — |
| EV/EBITDA | 24.51 | 24.51 | 28.93 | — | — |
| P/B | 1.32 | 1.32 | 2.85 | 4.68 | 5.68 |
| Growth & Yield | |||||
| Revenue Growth | 8.1% | 8.1% | 17.5% | 19.8% | — |
| EPS Growth | — | — | 160.9% | 65.7% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-43.5%
Start / end P/E
n/dx → n/dx
EPS bridge
0.14 → n/d
Residual
-43.5%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.